CN1843384A - Tetraselmis chui polysaccharide protein possessing antineoplastic function - Google Patents
Tetraselmis chui polysaccharide protein possessing antineoplastic function Download PDFInfo
- Publication number
- CN1843384A CN1843384A CN 200610046501 CN200610046501A CN1843384A CN 1843384 A CN1843384 A CN 1843384A CN 200610046501 CN200610046501 CN 200610046501 CN 200610046501 A CN200610046501 A CN 200610046501A CN 1843384 A CN1843384 A CN 1843384A
- Authority
- CN
- China
- Prior art keywords
- protein
- polysaccharide
- platymonas
- water
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention belongs to field of biological chemical industry, relating to proteinpolysaccharide, which is extracted from fresh flat algae through water scrubbing, freezing and thawing, foreigh protein removing, precipitation with alcohol, washing with acetone and drying with water bath. It is lacte powder, water soluble and alcohol, acetone and other organic dissolvent insoluble. The polysaccharide content is 40-70%, protein content is 10-30%, polysaccharide in water is 110-130 mg/ 100g water, and the adhesive degree is similar to that of water. The inhibiting rate to QGY-7701 liver cancer cell cultured external body and K562 erythroleukemia cell of said flat algae is 60-75%; and the cisplatin consumption amount can be reduced by 70-75% on condition of not reducing inhibiting rate. The inhibiting rate to BL/C57 melanomatosis in mouse of said flat algae is 36-40%, and it can also promote mouse growth.
Description
Technical field
The invention belongs to biological chemical field, relate to GL-PP, particularly a kind of GL-PP that from fresh ocean marine green alga, extracts.
Background technology
The photosynthetic utilization ratio height of microalgae, individual little, nutritious, growth and breeding rapidly, strong to the adaptive capacity of environment, cultivate easily, many countries have successively carried out microalgae cultivation, nutritive value analysis and development and use research, have obtained many achievements and progress.At present, the microalgae that has been widely studied and has developed comprises: chlorella (Chlorela sp.), spirulina (Spirulin sp.), Dunaliella salina (Dunaliella sp.), Haematococcus Pluvialis (Haematococcus sp.) etc., a large amount of broad-spectrum products have therefrom been produced, as food additive, health food, insecticide, plant growth regulator and antibiotic, antiviral and cancer-resisting substance.Yet, also have many and a large amount of microalgae that is not developed and studies, wherein contain a large amount of novel substances of not being familiar with and finding or the new approach that utilizes with uniqueness or efficient effect by people.As the good bait marine green alga of cultivating as the precious marine product germling (Platymonas subcordiformis), just contain some be not familiar with by people and finds have uniqueness or the novel substance that efficiently acts on or a new approach that utilizes.
Summary of the invention
The object of the present invention is to provide a kind of Platymonas sp.polysaccharide-protein that from fresh ocean marine green alga cell, extracts.
It is the antitumor medicine composition that is used for of active component with this Platymonas sp.polysaccharide-protein that another object of the present invention has provided a kind of.
Further aim of the present invention has provided above-mentioned Platymonas sp.polysaccharide-protein and has contained the purposes of compositions aspect antitumor drug of above-mentioned GL-PP.
The technical solution adopted for the present invention to solve the technical problems is to utilize fresh ocean marine green alga, extracts the powder of the light oyster white that forms through washed with de-ionized water, infiltration, freeze thawing, foreigh protein removing, ethanol precipitation, washing with acetone and precipitation dry run; Polyoses content is 40-70% in this Platymonas sp.polysaccharide-protein, protein content is 10-30%, dissolubility in water is a 110-130mg/100 gram water, viscosity approaches the viscosity of water, and sds gel electrophoresis shows and contains molecular weight in this Platymonas sp.polysaccharide-protein respectively at two kinds of glycoproteins of 2.8-3.2 ten thousand and 3.8-4.2 ten thousand.The preferred Platymonas sp.polysaccharide-protein of the present invention is that polyoses content is 50-55%, and protein content is 16-20%, and contains mean molecule quantity in this Platymonas sp.polysaccharide-protein and be respectively two kinds of GL-PP of 30,000 and 40,000.Dissolubility in the polyoses content of this Platymonas sp.polysaccharide-protein, protein content, the water changes relevant with factors such as trophophase and leaching process with the place of production, the growing environment of ocean marine green alga with molecular weight.
Platymonas sp.polysaccharide-protein of the present invention is used for tumor cell in vitro and mouse interior tumor cell are carried out the inhibitory action experiment, finds its QGY-7701 hepatoma carcinoma cell, erythroleukemia K In vitro culture
562The cell inhibiting rate is 60-75%, and Electronic Speculum shows that repressed tumor cell presents the obvious apoptosis feature, and promptly cell membrane bubbles, the nuclear chromatin pyknosis, and periphery is assembled, and karyorrhexis becomes bulk to intersperse among endochylema, forms apoptotic body.When this Platymonas sp.polysaccharide-protein and cisplatin combined use, under the prerequisite that does not reduce suppression ratio, can reduce the 70-75% of cisplatin use amount.This Platymonas sp.polysaccharide-protein is used for mouse inbred lines BL/C
57Melanoma is carried out inhibitory action research in the body, finds that its suppression ratio to tumor is 36-40%, and can impel the growth of mice.
It is active component that pharmaceutical composition of the present invention contains the above-mentioned Platymonas sp.polysaccharide-protein for the treatment of effective dose, and contains one or more pharmaceutically acceptable carriers.
Platymonas sp.polysaccharide-protein of the present invention and pharmaceutical compositions can be used for preparing various anti-tumor drugs.
The mixture of Platymonas sp.polysaccharide-protein of the present invention and cisplatin and the pharmaceutical compositions that contains this mixture thereof can be used for preparing various anti-tumor drugs.
Above-mentioned described pharmaceutically acceptable carrier is meant the pharmaceutical carrier of pharmaceutical field routine, comprises diluent, excipient such as water etc.; Filler such as starch, sucrose etc.; Adhesive such as cellulose and derivant, gelatin; Wetting agent such as glycerol; Disintegrating agent such as sodium bicarbonate, calcium carbonate etc.; Absorption enhancer such as quaternary ammonium salt; Surfactant such as high-carbon fatty alcohol; Absorption carrier such as Kaolin, soap clay; Lubricant such as Pulvis Talci, calcium stearate and poly-hexanediol etc.; Can also in compositions, add other adjuvant such as sweeting agent, flavouring agent etc.
Platymonas sp.polysaccharide-protein of the present invention can be applied to the treatment of tumor patient with the form of compositions by oral, rectum, vein, muscle or parenteral mode.Also can be according to the conventional production method of pharmaceutical field, as make its active component and one or more carriers or medicament mixed, prepare various dosage forms such as tablet, electuary, capsule, suppository, spray etc., preferred form is tablet, electuary, capsule, suppository, spray, slow releasing agent and injection; Particularly preferably be oral capsule.The active component that contains weight ratio in the pharmaceutical composition of the present invention and be 1%-99.5% is a Platymonas sp.polysaccharide-protein of the present invention, the active component that preferably contains weight ratio and be 45%-99.5% is a Platymonas sp.polysaccharide-protein of the present invention, and the active component that preferably contains weight ratio and be 90%-99.5% is a Platymonas sp.polysaccharide-protein of the present invention.
Formulation rate of the present invention can be according to variations such as route of administration, patient age, body weight, disease type and the orders of severity.
The specific embodiment
The following examples can help those skilled in the art more fully to understand the present invention, but do not limit the present invention in any way.
Embodiment 1. utilizes fresh ocean marine green alga, through washed with de-ionized water, infiltration, freeze thawing, centrifugal go algae mud, supernatant saltout foreigh protein removing, supernatant through dehydrated alcohol precipitate, acetone secondary washing precipitation and precipitation drying steps make Platymonas sp.polysaccharide-protein light oyster white powder, it consists of: polyoses content is 40%, and protein content is 30%.Dissolubility in water is a 100mg/100 gram water, and viscosity approaches the viscosity of water, and contains mean molecule quantity in this Platymonas sp.polysaccharide-protein and be respectively two kinds of GL-PP of 2.8 ten thousand and 4.2 ten thousand.
Embodiment 2. utilizes fresh ocean marine green alga, saltout foreigh protein removing, concentrated supernatant after secondary dehydrated alcohol precipitation, acetone secondary washing precipitation and precipitation drying steps make Platymonas sp.polysaccharide-protein light oyster white powder through washed with de-ionized water, infiltration, freeze thawing, centrifugal algae mud, the supernatant of going, it consists of: polyoses content is 70%, and protein content is 10%.Dissolubility in water is a 120mg/100 gram water, and viscosity approaches the viscosity of water, and contains mean molecule quantity in this Platymonas sp.polysaccharide-protein and be respectively two kinds of GL-PP of 3.2 ten thousand and 3.8 ten thousand.
Embodiment 3. utilizes fresh ocean marine green alga, through washed with de-ionized water, infiltration, freeze thawing, centrifugally saltout foreigh protein removing, concentrated supernatant after secondary dehydrated alcohol precipitation, three washing precipitations of acetone and precipitation drying steps make Platymonas sp.polysaccharide-protein light oyster white powder after removing algae mud, concentrated supernatant, it consists of: polyoses content is 55%, and protein content is 20%.Dissolubility in water is a 130mg/100 gram water, and viscosity approaches the viscosity of water, and contains mean molecule quantity in this Platymonas sp.polysaccharide-protein and be respectively two kinds of GL-PP of 2.8 ten thousand and 3.8 ten thousand.
The preparation of experimental example 4. antitumor tablets: get the Platymonas sp.polysaccharide-protein 10g of embodiment 1 preparation, add the medicinal cyclodextrin 30g of excipient, mix homogeneously, the pelletize tabletting makes tablet.
The capsular preparation of embodiment 5. antitumor: get the Platymonas sp.polysaccharide-protein 10g of embodiment 1 preparation, add the medicinal cyclodextrin 10g of excipient, mix homogeneously, pelletize incapsulates.
The preparation of embodiment 6. antitumor injections: get the Platymonas sp.polysaccharide-protein 1.1g of embodiment 3 preparations, add water for injection 1000ml, dissolving, membrane filtration; Packing, every bottle of 2ml.All operations all should carry out under aseptic condition.
The capsular preparation of embodiment 7. antitumor: get the Platymonas sp.polysaccharide-protein 6g of embodiment 2 preparations, cisplatin 2 grams add the medicinal cyclodextrin 10g of excipient, mix homogeneously, and pelletize incapsulates.
Claims (5)
1. GL-PP with antitumor action, it is characterized in that utilizing fresh ocean marine green alga, extract the powder of the light oyster white that forms through washed with de-ionized water, infiltration, freeze thawing, foreigh protein removing, ethanol precipitation, washing with acetone and precipitation dry run; Polyoses content is 40-70% in this Platymonas sp.polysaccharide-protein, protein content is 10-30%, dissolubility in water is a 110-130mg/100 gram water, viscosity approaches the viscosity of water, and sds gel electrophoresis shows and contains molecular weight in this Platymonas sp.polysaccharide-protein respectively at two kinds of glycoproteins of 2.8-3.2 ten thousand and 3.8-4.2 ten thousand.
2. Platymonas sp.polysaccharide-protein according to claim 1 is characterized in that polyoses content is 50-55%, and protein content is 16-20%, and contains mean molecule quantity in this Platymonas sp.polysaccharide-protein and be respectively two kinds of GL-PP of 30,000 and 40,000.
3. Platymonas sp.polysaccharide-protein is used in the preparation antitumor drug in the claim 1 or 2.
4. be used for antitumor medicine composition, it is characterized in that wherein containing the claim 1 for the treatment of effective dose or 2 Platymonas sp.polysaccharide-protein and pharmaceutically acceptable carrier.
5. pharmaceutical composition according to claim 4 is characterized in that wherein containing the claim 1 for the treatment of effective dose or 2 Platymonas sp.polysaccharide-protein and cisplatin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100465019A CN100525782C (en) | 2006-04-29 | 2006-04-29 | Tetraselmis chui polysaccharide protein possessing antineoplastic function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100465019A CN100525782C (en) | 2006-04-29 | 2006-04-29 | Tetraselmis chui polysaccharide protein possessing antineoplastic function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1843384A true CN1843384A (en) | 2006-10-11 |
| CN100525782C CN100525782C (en) | 2009-08-12 |
Family
ID=37062370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100465019A Expired - Fee Related CN100525782C (en) | 2006-04-29 | 2006-04-29 | Tetraselmis chui polysaccharide protein possessing antineoplastic function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100525782C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105542024A (en) * | 2016-01-06 | 2016-05-04 | 上海交通大学 | Red alga gracilariopsis lemaneiformis polysaccharide and preparation thereof, anti-tumor activity detection method and application |
| CN112587546A (en) * | 2020-12-30 | 2021-04-02 | 南方海洋科学与工程广东省实验室(湛江) | Application of tetraselmis selenylation exopolysaccharide in treatment of lung cancer |
-
2006
- 2006-04-29 CN CNB2006100465019A patent/CN100525782C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105542024A (en) * | 2016-01-06 | 2016-05-04 | 上海交通大学 | Red alga gracilariopsis lemaneiformis polysaccharide and preparation thereof, anti-tumor activity detection method and application |
| CN112587546A (en) * | 2020-12-30 | 2021-04-02 | 南方海洋科学与工程广东省实验室(湛江) | Application of tetraselmis selenylation exopolysaccharide in treatment of lung cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100525782C (en) | 2009-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101301310B (en) | Use of brown alga polysaccharide sulfate in preventing and treating Parkinson's disease | |
| KR101512495B1 (en) | Applications of arctigenin in formulating medicines for preventing or treating diseases related to red blood cell reduction | |
| Torres et al. | Fucoidans: The importance of processing on their anti-tumoral properties | |
| JP6600626B2 (en) | Methods for obtaining plant extracts and related compositions | |
| CN102743741A (en) | Preparation of blattodea polypeptide, and uses of the same in anti-gram-positive bacteria and anti-gram-negative bacteria | |
| CN104042567A (en) | Ampelopsin nano-micelle and application thereof | |
| CN102558391A (en) | Vitamin E succinate-chitosan graft and preparation method and application thereof | |
| Alamgir et al. | Bioactive compounds and pharmaceutical excipients derived from animals, marine organisms, microorganisms, minerals, synthesized compounds, and pharmaceutical drugs | |
| CN100525782C (en) | Tetraselmis chui polysaccharide protein possessing antineoplastic function | |
| CN108815218B (en) | Pharmaceutical composition and use thereof | |
| US20240166882A1 (en) | Colour-stable preparation of a magnesium chlorophyllin alkali metal salt or alkali earth metal salt from natural sources of chlorophyll | |
| CN102475698B (en) | Application of salvianolic acid L in preparation of medicines used for treating tumor | |
| CN110590908B (en) | Micropterus-derived antibacterial peptide additive and preparation method thereof | |
| CN111743924A (en) | Marine plant extract for treating diabetes, composition and application | |
| CN106748939A (en) | The new bromine phenol thiosemicarbazide compound of one class and its preparation and medicine and purposes | |
| CN1810842A (en) | Longleaf Grateloupia acuminata polysaccharide extract and its prepn and use | |
| CN1120908A (en) | Choice seafood extract product and its production process and uses | |
| CN102526714B (en) | Medicine composition for curing tumour and preparation method thereof | |
| WO2018012773A1 (en) | Anti-inflammatory composition containing uldavioside a compound | |
| JPWO2005027937A1 (en) | Glycolipid-containing composition, use thereof, and production method thereof | |
| CN104829679B (en) | A kind of water-soluble celastrin derivative and application thereof | |
| CN113116873B (en) | New use of aloe-emodin as anti-mast cell activator | |
| CN108721339A (en) | Remove internal grease Euglena extract and preparation method thereof | |
| CN109350620B (en) | A kind of drug and application thereof for treating oophoroma | |
| CN115397263B (en) | Composition containing N-acetylglucosamine and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090812 Termination date: 20100429 |